Author: Chris

GREY WOLF ANIMAL HEALTH REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS

Toronto, Ontario – March 17, 2022 – Magen Ventures I Inc. (TSXV:MAGN.P) (“Magen”) and Grey Wolf Animal Health Inc. (“Grey Wolf”) are pleased to announce that, further to Magen’s news release of January 26, 2022, they have entered into a business combination agreement dated March 16, 2022 (the “BCA”), which outlines the terms and conditions pursuant to which Magen and Grey Wolf will complete a transaction that will result in a reverse take-over of Magen by Grey Wolf (the “Proposed Transaction”). The Proposed Transaction will be an arm’s length transaction, and, if completed, will constitute Magen’s “Qualifying Transaction” (as such term is defined in Policy 2.4 of the TSX Venture Exchange (the “TSXV”)). Magen following the completion of the Proposed Transaction is referred to as the “Resulting Issuer”.

Read More »

GREY WOLF ANIMAL HEALTH REPORTS FOURTH QUARTER AND YEAR END 2022 FINANCIAL RESULTS

Toronto, Ontario – March 17, 2022 – Magen Ventures I Inc. (TSXV:MAGN.P) (“Magen”) and Grey Wolf Animal Health Inc. (“Grey Wolf”) are pleased to announce that, further to Magen’s news release of January 26, 2022, they have entered into a business combination agreement dated March 16, 2022 (the “BCA”), which outlines the terms and conditions pursuant to which Magen and Grey Wolf will complete a transaction that will result in a reverse take-over of Magen by Grey Wolf (the “Proposed Transaction”). The Proposed Transaction will be an arm’s length transaction, and, if completed, will constitute Magen’s “Qualifying Transaction” (as such term is defined in Policy 2.4 of the TSX Venture Exchange (the “TSXV”)). Magen following the completion of the Proposed Transaction is referred to as the “Resulting Issuer”.

Read More »

GREY WOLF ANIMAL HEALTH TO PRESENT AT THE 2023 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE

Toronto, Ontario – March 17, 2022 – Magen Ventures I Inc. (TSXV:MAGN.P) (“Magen”) and Grey Wolf Animal Health Inc. (“Grey Wolf”) are pleased to announce that, further to Magen’s news release of January 26, 2022, they have entered into a business combination agreement dated March 16, 2022 (the “BCA”), which outlines the terms and conditions pursuant to which Magen and Grey Wolf will complete a transaction that will result in a reverse take-over of Magen by Grey Wolf (the “Proposed Transaction”). The Proposed Transaction will be an arm’s length transaction, and, if completed, will constitute Magen’s “Qualifying Transaction” (as such term is defined in Policy 2.4 of the TSX Venture Exchange (the “TSXV”)). Magen following the completion of the Proposed Transaction is referred to as the “Resulting Issuer”.

Read More »

GREY WOLF ANIMAL HEALTH REPORTS FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2022

Toronto, Ontario – March 17, 2022 – Magen Ventures I Inc. (TSXV:MAGN.P) (“Magen”) and Grey Wolf Animal Health Inc. (“Grey Wolf”) are pleased to announce that, further to Magen’s news release of January 26, 2022, they have entered into a business combination agreement dated March 16, 2022 (the “BCA”), which outlines the terms and conditions pursuant to which Magen and Grey Wolf will complete a transaction that will result in a reverse take-over of Magen by Grey Wolf (the “Proposed Transaction”). The Proposed Transaction will be an arm’s length transaction, and, if completed, will constitute Magen’s “Qualifying Transaction” (as such term is defined in Policy 2.4 of the TSX Venture Exchange (the “TSXV”)). Magen following the completion of the Proposed Transaction is referred to as the “Resulting Issuer”.

Read More »

Magen Ventures Enters into Letter of Intent for Qualifying Transaction with Grey Wolf Animal Health Inc.

TORONTO, ONTARIO – January 26, 2022 – Magen Ventures I Inc. (TSXV: MAGN.P) (“Magen” or the “Company”) and Grey Wolf Animal Health Inc. (“Grey Wolf” or the “Target”) are pleased to announce that they have entered into a non-binding letter of intent dated January 26, 2022 (the “LOI”), pursuant to which Magen and Grey Wolf intend to complete a business combination or other similarly structured transaction which will constitute a reverse take-over of Magen (the “Transaction”). It is intended that the Transaction will be an arm’s length “Qualifying Transaction” for Magen, as such term is defined in Policy 2.4 – Capital Pool Companies of the TSX Venture Exchange (the “TSXV”).

Read More »

New! Ataject™ and Sedaject™

Grey Wolf Animal Health is pleased to announce the launch of SEDAJECT™ and ATAJECT™ in the Canadian veterinary market. SEDAJECT™ (dexmedetomidine hydrochloride injection, 0.5 mg/ml) is a sedative and analgesic used in dogs and cats to facilitate clinical examinations, clinical procedures, minor surgical procedures, and minor dental procedures. It is also indicated for use as […]

Read More »
Greywolf community greater than covid 19
5-fall-safety-tips
greywolf you never know when your pet will get sick
greywolf worried your pet will have diarrhea
greywolf 5-tips-for-minimizing-stress-fall
Greywolf logo did you know that gi upset is the number one reason for unplanned vet visits